Melane Sampson, Author at BioTuesdays

Developments

Lively X discussion about the clinical potential of Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgeries helps drive stock

Perimeter Medical Imaging AI’s (TSX-V:PINK; OTC:PYNKF) ultra-high-res imaging tool for use during breast cancer surgeries was highlighted in a conversation today on X driven by renowned Silicon Valley venture...

February 4, 2025

Developments

Pyxis initiates new combination trial; expands existing monotherapy trial

Pyxis Oncology (NASDAQ:PYXS) has announced the initiation of a Phase 1/2 combination trial of its PYX-201 in conjunction with Merk’s (NYSE: MRK) anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of multiple...

February 4, 2025

Executive Moves

Therma Bright adds Steve Raysely to advisory board

Therma Bright (TSXV:THRM; OTCQB:TBRIF) has announced the appointment of Steve Raysely to its advisory board. Mr. Raysely brings senior executive expertise in healthcare technology sales, marketing, and operations to the...

February 4, 2025

Executive Moves

Tonix names Siobhan Fogarty as CTO

Tonix Pharmaceuticals (NASDAQ:TNXP) has announced the appointment of Siobhan Fogarty as chief technical officer (CTO), effective immediately. Previously serving as executive vice president of product development at...

February 4, 2025

Feature

MOBILion trailblazing next-gen separation science to reveal what others leave unseen

Closely held MOBILion Systems is redefining analytical characterization through its next-generation separation science platform that is integrated with high-resolution mass spectrometry to achieve unprecedented...

February 4, 2025

Developments

uniQure completes enrollment for Phase 1/2a trial of gene therapy in Fabry disease

uniQure (NASDAQ:QURE) has announced the completion of enrollment for its Phase 1/2a trial of AMT-191 in patients with Fabry disease. The company also reports receiving a favorable recommendation from the Independent...

February 3, 2025

Developments

Vanda and Anaptys ink licencing agreement for commercialization of imsidolimab in GPP

Vanda Pharmaceuticals (NASDAQ:VNDA) and AnaptysBio (NASDAQ: ANAB) have announced an exclusive global licencing agreement granting Vanda the rights to commercialize imsidolimab, a treatment for generalized pustular...

February 3, 2025

Developments

Fractyl increases focus on key gene therapy programs

Fractyl Health (NASDAQ:GUTS) has announced plans to prioritize its REMAIN-1 pivotal study, advance its novel Rejuva gene therapy platform into first-in-human studies, and pause investment in its Revita programs for Type...

January 31, 2025

Developments

INBS upgrades portable drug screening reader with multilingual capabilities

Intelligent Bio Solutions (INBS) (NASDAQ:INBS) has announced plans to upgrade its drug screening reader, the Intelligent Fingerprinting Drug Screening System, to support multiple languages across North and South...

January 31, 2025

Developments

HeartBeam files 510(k) application with FDA for ECG software

HeartBeam (NASDAQ:BEAT) has announced the submission of a 510(K) application to the FDA for its 12-lead electrocardiogram (ECG) synthesis software, designed to analyze diverse cardiac rhythms and arrhythmias, leveraging...

January 30, 2025

Author - Melane Sampson

Lively X discussion about the clinical potential of Perimeter’s AI-driven, wide field OCT margin visualization technology during breast cancer surgeries helps drive stock

Pyxis initiates new combination trial; expands existing monotherapy trial

Therma Bright adds Steve Raysely to advisory board

Tonix names Siobhan Fogarty as CTO

MOBILion trailblazing next-gen separation science to reveal what others leave unseen

uniQure completes enrollment for Phase 1/2a trial of gene therapy in Fabry disease

Vanda and Anaptys ink licencing agreement for commercialization of imsidolimab in GPP

Fractyl increases focus on key gene therapy programs

INBS upgrades portable drug screening reader with multilingual capabilities

HeartBeam files 510(k) application with FDA for ECG software

Subscribe